Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06906887 · ClinicalTrials.gov registry record · Phase 2
PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer
A Phase 2 study of Esophageal Cancer and GastroEsophageal Cancer, sponsored by Medical College of Wisconsin.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT06906887 is a Phase 2 study of Esophageal Cancer and GastroEsophageal Cancer that is actively recruiting participants, run by Medical College of Wisconsin. The registered enrollment target is 50 participants, below the 499-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06906887, a Phase 2 study of Esophageal Cancer and GastroEsophageal Cancer, is actively recruiting participants, sponsored by Medical College of Wisconsin.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, randomized, open-label, two-arm phase 2 trial that will evaluate whether the use of Pulsed Low-Dose-Rate radiation technique, as compared to standard radiation, is associated with reduced rates of clinically significant esophagitis during and following chemoradiation.
Conditions Studied
Interventions
- DRUG Chemotherapy
- PROCEDURE Surgery
- DRUG Induction Chemotherapy (modified FLOT or modified FOLFOX-6)
- RADIATION Conventional Radiation
- RADIATION Pulsed Low-Dose-Rate (PLDR) Radiation
Study Locations (1)
Wisconsin
- Froedtert & the Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-06-17 |
| Est. Completion | 2032-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06906887
The ClinicalTrials.gov registry entry for NCT06906887 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 499-participant average among 123 other Esophageal Cancer trials with a reported enrollment target (90% lower). The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Esophageal Cancer appearing as the primary indexed condition, and to 5 interventions - of which Chemotherapy is the first listed.
NCT06906887 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06906887 about?
NCT06906887 is a clinical study titled "PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer". This is a prospective, randomized, open-label, two-arm phase 2 trial that will evaluate whether the use of Pulsed Low-Dose-Rate radiation technique, as compared to standard radiation, is associated with reduced rates of clinically significant esophagitis during and following chemoradiation.
What is the current status of trial NCT06906887?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2025-06-17. Estimated completion is 2032-06-01.
What conditions does trial NCT06906887 study?
This clinical trial studies the following conditions: Esophageal Cancer, GastroEsophageal Cancer, Oesophageal Cancer.
What interventions are being tested in trial NCT06906887?
The interventions under investigation include: Chemotherapy (DRUG), Surgery (PROCEDURE), Induction Chemotherapy (modified FLOT or modified FOLFOX-6) (DRUG), Conventional Radiation (RADIATION), Pulsed Low-Dose-Rate (PLDR) Radiation (RADIATION).
Who is sponsoring clinical trial NCT06906887?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06906887 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Single Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer.
RECRUITING · Phase 2
-
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
RECRUITING · Phase 2
-
Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
RECRUITING · Phase 2
-
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
RECRUITING · Phase 2
-
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 2
-
Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers
ACTIVE NOT RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.